InSymbiosis’ Investment Vehicle (formalized in 2016 as InSynchrony Ventures Inc.) tactically combines InSymbiosis’ successful business model with our desire to accelerate promising early stage drug assets towards clinical proof of concept and strategic exits.Contact Our Investment Team
As investors, we are opportunistic and we therefore do not have a particular therapeutic bias. We are interested in meeting companies with therapeutic products in development that have achieved a minimum of animal proof of concept and have a clearly defined drug development plan and commercial exit strategy.
MHB Labs is a Boston based biopharmaceutical start-up founded by leading men’s health physicians seeking to develop superior treatments for hypogonadism (low testosterone). They have developed AndroSphere, the first extended release form of human chorionic gonadotropin, which has attractive features that could make it a market leader and a new standard for the treatment of low testosterone.
Genoa Pharmaceuticals is a San Diego-based pharmaceutical company developing improved therapies for the treatment of Idiopathic Pulmonary Fibrosis.
Cetya Therapeutics is a US based drug development company developing next generation HDAC inhibitors for oncology. Cetya can target their drug candidates to particular cell types or tumors which is unique to Cetya and differentiates them from other HDAC inhibitor companies. Targeting can reduce toxicity and, as a result, open up new therapeutic areas outside of oncology to treatment with HDAC inhibitors, such as sickle cell disease or Parkinson’s.
Vaxdyn is a Spanish based biotechnology company committed to tackling the global health problems associated with infections resistant to antibiotics by creating immunity in the population. Vaxdyn has a unique platform for the development of preventive vaccines against the most worrisome and difficult to control bacteria: Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and pathogenic E. coli. The vaccines are based on whole cells devoid of toxicity and presenting multiple conserved antigens on their surface.
Atriva Therapeutics is a German based drug development company that is developing the next generation of antiviral therapies. Their product platform is based on a variety of different MEK kinase inhibitors focusing on severe viral infections that are potentially applicable for use with high-risk influenza patients. Atriva was founded in 2015 by a group of renowned virologist and European serial entrepreneurs and experts from life-science industry.